Article Details
Retrieved on: 2025-01-09 17:58:21
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Parvus Therapeutics' development of PVT401, an autoimmune drug for inflammatory bowel disease (IBD). It highlights the company’s broader focus on pMHC nanomedicines to induce Treg cells, relevant to autoimmune diseases like type 1 diabetes, linking to tags like 'T cells' and 'Regulatory T cell'.
Article found on: www.pharmaceutical-business-review.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here